A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

A high-throughput platform would greatly facilitate COVID-19 serological testing and antiviral screening. Here we report a nanoluciferase SARS-CoV-2 (SARS-CoV-2-Nluc) that is genetically stable and replicates similarly to the wild-type virus in cell culture. We demonstrate that the optimized reporte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:bioRxiv
Autors principals: Xie, Xuping, Muruato, Antonio E., Zhang, Xianwen, Lokugamage, Kumari G., Fontes-Garfias, Camila R., Zou, Jing, Liu, Jianying, Ren, Ping, Balakrishnan, Mini, Cihlar, Tomas, Tseng, Chien-Te K., Makino, Shinji, Menachery, Vineet D., Bilello, John P., Shi, Pei-Yong
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325177/
https://ncbi.nlm.nih.gov/pubmed/32607511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.22.165712
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars